Last reviewed · How we verify
IV Potassium Canrenoate
At a glance
| Generic name | IV Potassium Canrenoate |
|---|---|
| Also known as | Drug |
| Sponsor | Pr. Nicolas GIRERD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Potassium Canrenoate in Brain-dead Organ Donors: Randomized Controlled Clinical Trial (PHASE2)
- A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients (PHASE4)
- Clinical Efficacy of Potassium Canrenoate in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation. (PHASE4)
- Aldosterone Blockade Early After Acute Myocardial Infarction (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Potassium Canrenoate CI brief — competitive landscape report
- IV Potassium Canrenoate updates RSS · CI watch RSS
- Pr. Nicolas GIRERD portfolio CI